– For todayNow you can listen to FOX news headlines!
A common vaccine may help fight cancer, new research suggests.
In cancer patients are attacked, the researchers found that they get the mrna vaccine
Researchers at the University of Florida and Texas MD Anderson Center analyzed data from 1,000 cancers with stage 3 and 4 melanomas treated at MD Anderson from 2023.
5 things you need to know before getting your flu shot, according to doctors
All patients are treated with anti-inflammatory drugs, a type of immunotherapy drug that helps the immune system recognize and attack tumor cells more effectively.
Some of the patients received the Mrna Covid vaccine within 100 days of starting immunotherapy and some did not, according to the study published in the study.
A common vaccine may help fight cancer, new research suggests. (Stock)
The investigators found that those who received both the vaccine and immunotherapy lived “by a significant amount.”
Those who received the vaccine had almost twice the median survival – 37.3 months compared to 20.6 months.
Contraindications and Contraindications Officials weigh dividing the MMR from the MMR into a single dose
The greatest survival benefit was seen in patients with physically “cold” tumors – those that were resistant to immunotherapy. Among those patients, the insertion of the mRNA vaccine was linked to an increase of almost five years with a three-year overall survival.
“At the time the data was collected, some patients were still alive, which means that the effect of the vaccine can be very strong,” it was released.
The researchers discovered that they were getting an mRNA vaccine (Stock)
The investigators then replicated this effect in mouse models – when the mice received a combination of immunotherapy drugs and an mRNA vaccine targeting the avid-19 spike protein, their tumors responded to the treatment.
“This is the type of treatment benefit that we strive for and hope to see with therapeutic interventions.”
Non-vaccines for influenza and pneumonia did not have those effects, the study found.
These findings were presented at the European Society for Medical Oncology (ESMO) Congress 2025 Congress in Berlin on Oct 19 and published in the journal Nature.
Click here for the FOX News app
“The results are unique – this could change the entire field of Oncologic care,” said senior researcher Elias Sayour, MD, Ph.D., UF Health Cancer / Bonnie R. Freeman Professios for Pediatric Oncology Research.
Since this was an observational study, the investigators noted that a clinical and randomized trial is needed to confirm the findings.
Click here to subscribe to our New Health Newsletter
“Although they have not been shown to be appropriate, this type of treatment is striving and we hope to see through therapeutic intervention – but rarely do,” said Duane Mitchell, Md, Ph.D.
“I think the urgency and importance of doing proven work cannot be overstated.”
All patients are treated with anti-inflammatory drugs, a type of immunotherapy drug that helps the immune system recognize and attack tumor cells more effectively. (Stock)
The researchers are now planning to launch a large clinical trial with the Eff-LED Fflorida + Network in the network, health centers and clinics in Florida, Alabama, California and Minnesota, said the release.
In the future, the researchers suggest that a “universal, off-the-shelf” vaccine could be developed to stimulate the immune system’s immune response.
Test yourself with our latest lifestyle quiz
“If this doubles what we’re getting now, or more – 5%, 10% – that means a lot for those patients, especially if this can be found in different cancers in different patients,” he added.
Click here for more health news
This study was supported in part by the National Institutes of Health and the National Cancer Institute, the drug and alcohol administration, the American Brain Tumor Association, and the radiological society of North America, among others.
